LON:OCTP Oxford Cannabinoid Technologies (OCTP) Share Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free OCTP Stock Alerts GBX 0.36 -0.01 (-2.67%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range 0.36▼ 0.3850-Day Range 0.33▼ 0.4952-Week Range 0.31▼ 1.55Volume4.12 million shsAverage Volume5.36 million shsMarket Capitalization£3.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Oxford Cannabinoid Technologies alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Oxford Cannabinoid Technologies Stock (LON:OCTP)Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. In addition, its development pipeline includes cannabinoid derivative products comprising OCT960609, a dual CB1 and CB2 agonist targeting an undisclosed neuropathic pain indications; and immunotherapy agents for the treatment of solid tumours. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.Read More OCTP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCTP Stock News HeadlinesOctober 15, 2023 | wsj.comOxford Cannabinoid Technologies Holdings PLCOctober 12, 2023 | benzinga.comWeed In Europe: Medical Marijuana In Ukraine, Albania's Hemp, UK Cannabis Study Lacks DiversityApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.October 10, 2023 | finance.yahoo.comOxford Cannabinoid Technologies CEO says objective "absolutely met" in lead asset trialOctober 10, 2023 | proactiveinvestors.comOxford Cannabinoid readies for next stage as it safely navigates phase I stduyOctober 10, 2023 | proactiveinvestors.comOxford Cannabinoid readies for next stage as it safely navigates phase I studySeptember 25, 2023 | finance.yahoo.comOxford Cannabinoid Technologies reports no adverse events in OCT461201 trialSeptember 1, 2023 | finance.yahoo.comOxford Cannabinoid Technologies in a "comfortable position" ahead of Phase 1 results releaseApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.August 31, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies hails defining year as...Oxford Cannabinoid Technologies hails defining year as clinical...July 28, 2023 | finance.yahoo.comOxford Cannabinoid Technologies "officially on the way" after first dosingJuly 27, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies takes pain drug into phase I; appoints leading pain expertJuly 24, 2023 | finance.yahoo.comOxford Cannabinoid Technologies announces "potential breakthrough" in field of oncologyJune 8, 2023 | proactiveinvestors.comOxford Cannabinoid appoints chief medical officerMay 18, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies reaches milestone with phase 1 trial approval for pain relief drugMay 17, 2023 | proactiveinvestors.comOxford Cannabinoid rise continues as first clincial trial gets startedApril 13, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies confirms CEO appointment, licence renewal and clinical progressApril 12, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies confirms Sowemimo-Coker as permanent CEOApril 12, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies shares spike on CEO appointment and licence renewalMarch 1, 2023 | finance.yahoo.comOxford Cannabinoid Technologies Holdings Plc (OCTP.L)February 10, 2023 | uk.investing.comOxford Cannabinoid Technologies Holdings PLC (OCTP)January 25, 2023 | lse.co.ukOxford Cannabinoid interim loss nearly doubles as research costs surgeJanuary 24, 2023 | proactiveinvestors.comProactive's John Savin publishes fresh research note on Oxford Cannabinoid TechnologiesJanuary 23, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies with "lots to look forward to" after interimsJanuary 12, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies "proceeding forward as planned" after review meetingJanuary 6, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies "ready to go" after phase 1 trial submissionJanuary 5, 2023 | proactiveinvestors.comOxford Cannabinoid Technologies hails 'milestone' as it submits Phase I trial application for lead programmeSee More Headlines Receive OCTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Cannabinoid Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:OCTP CUSIPN/A CIKN/A Webwww.oxcantech.com Phone44 20 3034 2820FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-4,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.76% Return on Assets-53.92% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio5.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,090,000,000Free FloatN/AMarket Cap£4.02 million OptionableNot Optionable Beta0.79 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Clarissa Ann Sowemimo-Coker (Age 44)CEO & Executive Director Comp: $215.67kMr. Paul William Smalley (Age 51)Finance Director & Executive Director Comp: $155.16kMr. Indraneil Mahapatra (Age 44)Co-Founder & Non-Executive Director Comp: $249.52kDr. Valentino Parravicini (Age 55)Chief Scientific Officer Mr. Robin BennettGeneral Counsel & Company SecretaryDr. Timothy H. Corn FFPM (Age 73)M.Sc., Executive Director & Chief Medical Officer More ExecutivesKey CompetitorsFusion AntibodiesLON:FABAptamer GroupLON:APTAMotif BioLON:MTFBIXICOLON:IXIValiRxLON:VALView All CompetitorsInsidersIndraneil (Neil) MahapatraSold 54,864,288 sharesTotal: £54.86 M ($1.00/share)Clarissa Ann Sowemimo- CokeBought 310,406 shares on 7/17/2023Total: £310,406.00 ($1.00/share)View All Insider Transactions OCTP Stock Analysis - Frequently Asked Questions How have OCTP shares performed in 2024? Oxford Cannabinoid Technologies' stock was trading at GBX 0.63 at the start of the year. Since then, OCTP shares have decreased by 41.6% and is now trading at GBX 0.37. View the best growth stocks for 2024 here. How do I buy shares of Oxford Cannabinoid Technologies? Shares of OCTP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:OCTP) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Cannabinoid Technologies Holdings Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
